# Ocular Pharmacology: Drug Delivery and Bioavailability

## Introduction

The eye presents unique pharmacological challenges due to its complex anatomy, multiple tissue barriers, and need for sustained drug concentrations at the target site. Understanding the principles of ocular drug delivery and bioavailability is essential for selecting the optimal route, formulation, and dosing strategy for ophthalmic therapeutics.

## Barriers to Ocular Drug Delivery

### Anterior Segment Barriers

**Tear film and precorneal drainage**: rapid turnover (16% per minute) reduces drug contact time; nasolacrimal drainage removes drug within 1-2 minutes. **Corneal epithelium**: tight junctions (zonulae occludentes) form the primary barrier to topical drug penetration; lipophilic drugs penetrate better. **Corneal stroma**: hydrophilic layer; presents a barrier to lipophilic drugs. **Corneal endothelium**: leaky barrier; less restrictive than epithelium. **Blood-aqueous barrier**: tight junctions of the iris vascular endothelium and non-pigmented ciliary epithelium; limits systemic drug entry into the anterior chamber.

### Posterior Segment Barriers

**Blood-retinal barrier (BRB)**: two components: Inner BRB: tight junctions of retinal capillary endothelium. Outer BRB: tight junctions of retinal pigment epithelium. Limits systemic drug penetration to the retina and vitreous. BRB breakdown in disease (diabetic retinopathy, uveitis) enhances drug entry but is not reliable for therapy. **Vitreous humor**: large, gel-like volume (4 mL) that slows drug diffusion.

### Other Factors Affecting Bioavailability

**Melanin binding**: drugs bind to melanin in the uvea and RPE (pilocarpine, atropine, timolol); creates a reservoir effect with prolonged release. **Efflux pumps**: P-glycoprotein on corneal and retinal epithelium limits intracellular drug accumulation. **Metabolic enzymes**: esterases in the cornea (prodrug activation), cytochrome P450.

## Routes of Ocular Drug Delivery

### Topical (Eyedrops)

Most common route for anterior segment disease. **Bioavailability**: only 1-5% of the applied dose reaches the aqueous humor. Factors affecting penetration: drop volume (ideal 20-30 microliters; most droppers deliver 40-50), lipophilicity, molecular weight, pH, formulation. **Contact time** is critical: gel formulations, ointments, and viscosity-enhancing agents (CMC, HPMC, polyvinyl alcohol) improve bioavailability. Punctal occlusion and eyelid closure for 2-3 minutes after instillation reduce systemic absorption by 50-70%.

### Subconjunctival

Bypasses the corneal epithelial barrier; drug depot in the subconjunctival space. Useful for: antibiotics (cefazolin, vancomycin), corticosteroids (dexamethasone, triamcinolone) Higher anterior segment concentrations than topical delivery. Drug may reach posterior segment via transscleral diffusion.

### Sub-Tenon (Posterior Sub-Tenon)

Injection into the sub-Tenon space posterior to the equator. Used for periocular corticosteroid delivery (triamcinolone acetonide 40 mg) Transscleral drug diffusion to the choroid, retina, and vitreous. Lower risk than intravitreal injection; useful for cystoid macular edema, uveitis.

### Intravitreal

Direct injection into the vitreous cavity; highest bioavailability for posterior segment. Standard for **anti-VEGF agents**, intravitreal corticosteroids, intravitreal antibiotics. Injection technique: topical anesthesia, povidone-iodine prep, 30-gauge needle, 3.5-4 mm posterior to the limbus. **Drug half-life** in the vitreous varies: ranibizumab approximately 9 days; bevacizumab approximately 10 days; triamcinolone approximately 18 days. Risks: endophthalmitis (0.02-0.05%), retinal detachment, vitreous hemorrhage, cataract.

### Intracameral

Injection into the anterior chamber (typically at the end of cataract surgery) Used for antibiotics (moxifloxacin, cefuroxime) and mydriatics (phenylephrine/ketorolac) Reduces endophthalmitis rates after cataract surgery (ESCRS study)

### Systemic (Oral and Intravenous)

Limited ocular bioavailability due to blood-ocular barriers. Required for: orbital disease, posterior scleritis, optic neuritis, endophthalmitis (adjunctive), uveitis. Oral acetazolamide achieves adequate ciliary body concentrations for IOP reduction. Systemic corticosteroids and immunosuppressives for intraocular inflammation.

| Route | Bioavailability | Target | Key Advantage | Key Limitation |
|---|---|---|---|---|
| Topical (eyedrops) | 1-5% to aqueous | Anterior segment | Non-invasive; patient self-administered | Rapid drainage; poor posterior penetration |
| Subconjunctival | Moderate (anterior) | Anterior segment, sclera | Bypasses corneal barrier; depot effect | Subconjunctival hemorrhage; discomfort |
| Sub-Tenon | Moderate (posterior) | Choroid, retina, vitreous | Lower risk than intravitreal; office procedure | Less predictable than intravitreal |
| Intravitreal | ~100% (vitreous) | Posterior segment | Highest posterior bioavailability | Invasive; endophthalmitis risk (0.02-0.05%) |
| Intracameral | High (AC) | Anterior chamber | Direct delivery; reduces endophthalmitis | Intraoperative only; limited volume |
| Systemic (oral/IV) | Low (ocular) | All ocular tissues | Required for orbital/systemic disease | Blood-ocular barriers; systemic side effects |

![Diagram illustrating ocular drug delivery routes and barrier systems](images/ocular-drug-delivery-routes.jpg)

## Sustained-Release Drug Delivery Systems

### Intravitreal Implants

**Dexamethasone intravitreal implant (Ozurdex)**: biodegradable; releases drug over 4-6 months. **Fluocinolone acetonide implant (Retisert)**: non-biodegradable; surgically implanted; 30-month duration. **Fluocinolone acetonide insert (Yutiq)**: non-biodegradable; injector-delivered; 36-month duration. **Ganciclovir implant (Vitrasert)**: historical use for CMV retinitis (replaced by systemic therapy)

### Port Delivery System

**Ranibizumab port delivery system (Susvimo)**: surgically implanted refillable reservoir in the sclera. Continuously delivers ranibizumab to the vitreous for approximately 6 months between refills. Reduces treatment burden for neovascular AMD (Archway trial)

### Punctal Plugs with Drug Delivery

Sustained release of drugs (travoprost, dexamethasone) from punctal plugs. Improves compliance by eliminating need for daily drops. Various designs in clinical trials.

### Nanoparticle and Liposomal Formulations

**Nanoparticles**: enhance corneal penetration, prolong drug contact, enable targeted delivery. **Liposomes**: encapsulate hydrophilic or lipophilic drugs; improve corneal uptake. **Cyclodextrin complexes**: improve aqueous solubility of lipophilic drugs (e.g., cyclosporine formulations) Emerging: mucoadhesive nanoparticles, dendrimer-based systems, hydrogel depots.

![Comparison of sustained-release intravitreal implant designs](images/sustained-release-implants-ocular.jpg)

## Pharmacokinetic Principles in Ocular Drug Design

### Prodrug Strategy

Inactive precursor converted to active drug by ocular enzymes. **Latanoprost**: isopropyl ester prodrug; activated by corneal esterases to latanoprost acid. **Dipivefrin**: prodrug of epinephrine; improved corneal penetration. **Nepafenac**: corneal esterases convert to amfenac (active NSAID)

### Henderson-Hasselbalch Equation

The ionized/unionized ratio of a drug at ocular surface pH (7.4) determines penetration. Unionized (non-ionized) fraction crosses lipid membranes more readily. Formulation pH affects both drug stability and patient comfort.

### Protein Binding

Drugs bound to aqueous humor proteins are pharmacologically inactive. **Inflammation** increases protein content of aqueous humor, potentially reducing free drug concentration.

## Toxicology Considerations

**Corneal epithelial toxicity**: preservatives (especially **benzalkonium chloride**, BAK) cause dose-dependent epithelial damage. Preservative-free formulations preferred for chronic use and sensitive eyes. **Retinal toxicity**: intravitreal aminoglycosides (gentamicin) can cause macular infarction; avoid in most circumstances. Chloroquine/hydroxychloroquine retinal toxicity (screening guidelines per AAO)

![Schematic of corneal drug penetration pathways: transcellular vs. paracellular](images/corneal-drug-penetration.jpg)

## Key Clinical Pearls

Only 1-5% of a topical eyedrop reaches the aqueous humor; punctal occlusion and eyelid closure significantly improve bioavailability. The corneal epithelium is the primary barrier to topical drug delivery; lipophilic drugs penetrate better than hydrophilic drugs. Intravitreal injection provides the highest bioavailability for posterior segment disease and is the standard route for anti-VEGF agents. Sustained-release implants and port delivery systems represent the future of reducing treatment burden in chronic posterior segment diseases.

## References

1. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. *AAPS J*. 2010;12(3):348-360.
2. Del Amo EM, Rimpela AK, Heikkinen E, et al. Pharmacokinetic aspects of retinal drug delivery. *Prog Retin Eye Res*. 2017;57:134-185.
3. Yellepeddi VK, Palakurthi S. Recent advances in topical ocular drug delivery. *J Ocul Pharmacol Ther*. 2016;32(2):67-82.
4. Holekamp NM, Campochiaro PA, Chang MA, et al. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. *Ophthalmology*. 2022;129(3):295-307.